Contact your healthcare provider if your symptoms significantly change after starting treatment or if you have any concerns
If you have not started tirzepatide treatment yet, consider starting with a single month paid in full before committing to financed multi-month packages
Carteron L, Solari D, Patet C, Quintard H, Miroz JP, Bloch J, et al
Key results at the highest dose (24 mg): 22.5% placebo-adjusted mean weight loss at 48 weeks 96% achieved at least 5% weight loss 87% achieved at least 10% weight loss 48% achieved at least 20% weight loss 26% achieved at least 30% weight loss 54% reduced BMI below the obesity threshold (30 kg/m2) versus 13% placebo No weight loss plateau at 48 weeks Discontinuation due to adverse events: 5.9% (CT-388) vs 1.3% (placebo) Preclinical Data# CT-388 improved glycemic control in mice and monkeys, reduced body weight, suppressed appetite, and improved metabolic dysfunction-associated steatohepatitis (MASH) pathology in mice
Among the total datasets in the Korean NHIS database, qualifications, claims, and health checkup databases were used
Normal carnitine levels in patients with chronic fatigue syndrome